$10.5 B

ALNY Mkt cap, 22-Jun-2018
Alnylam Pharmaceuticals Net income (Q1, 2018)-141.2 M
Alnylam Pharmaceuticals EBIT (Q1, 2018)-147.4 M
Alnylam Pharmaceuticals Cash, 31-Mar-2018396.1 M
Alnylam Pharmaceuticals EV10.1 B

Alnylam Pharmaceuticals Financials

Alnylam Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

382.4 b390.6 m

General and administrative expense

89.4 b199.4 m

Operating expense total

471.7 b590 m

EBIT

(92.9 m)(405 m)(296 m)(424.6 b)(500.1 m)

Interest income

8.3 b12.2 m

Pre tax profit

(410.1 b)

Net Income

(89.2 m)(360.4 m)(290.1 m)(410.1 b)(490.9 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

34.5 m43.8 m44.7 m46.3 m58 m67 m68.6 m96.3 m83.2 m97.9 m87 m90.6 m96.9 m

General and administrative expense

6.8 m8.9 m11.5 m9.9 m12.7 m14.6 m16 m21.1 m18 m22.4 m38.5 m45.8 m72.4 m

Operating expense total

41.2 m277.3 m52.3 m56.2 m70.8 m81.6 m84.7 m117.4 m101.2 m120.3 m125.5 m136.4 m169.3 m

EBIT

(32.2 m)(269.1 m)(45 m)(45.2 m)(52.2 m)(72.9 m)(78.3 m)(110 m)(92.5 m)(106.7 m)(106.5 m)(120.5 m)(147.4 m)

Interest income

290 k333 k693 k753 k1 m1.6 m1.6 m1.8 m2.1 m2.2 m2.1 m2.6 m5.8 m

Pre tax profit

(32 m)(268.8 m)(44.4 m)(43.9 m)(51.2 m)(71.4 m)(76.8 m)(103 m)(90.1 m)(141.3 m)

Income tax expense

(431 k)62 k

Net Income

(29.7 m)(250.9 m)(44.1 m)(44 m)(50.8 m)(71.8 m)(76.8 m)(103 m)(90.1 m)(104.1 m)(107.3 m)(118.4 m)(141.2 m)

Alnylam Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

53.2 m75.2 m180.9 m193.6 m645.4 m

Accounts Receivable

17.9 m

Inventories

3.9 m9.7 m16.6 m21.7 m

Current Assets

254 m746.4 m1.1 b671.9 m1.8 b

PP&E

16.4 m21.7 m27.8 m114.6 m181.9 m

Total Assets

420.5 m1.1 b1.4 b1.3 b2 b

Accounts Payable

5.9 m15.1 m16.8 m54.5 m28.4 m

Short-term debt

Current Liabilities

53.9 m95.3 m62.1 m131.7 m144.3 m

Long-term debt

150 m30 m

Total Debt

150 m30 m

Total Liabilities

342.6 m228.3 m

Additional Paid-in Capital

846.2 m1.8 b2.5 b2.6 b3.9 b

Retained Earnings

(596.2 m)(956.6 m)(1.2 b)(1.7 b)(2.1 b)

Total Equity

270.3 m936.3 m1.3 b920.2 m1.8 b

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.6 x1.2 x1.1 x1.4 x1.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

11.8 m350.6 m80.7 m82.7 m306.6 m151.3 m149.2 m231.3 m271.1 m168.5 m171.1 m408.7 m396.1 m

Current Assets

199.2 m674.1 m665.1 m643 m1.1 b1 b1 b1.1 b888.1 m747.6 m597.2 m960.7 m1.7 b

PP&E

17 m15.7 m17 m18.8 m21.2 m25.2 m26.3 m36.8 m55.4 m74.2 m130 m147.5 m202 m

Total Assets

447.5 m1.1 b1 b986.4 m1.6 b1.5 b1.4 b1.3 b1.4 b1.3 b1.1 b1.4 b1.9 b

Accounts Payable

2.7 m5 m6.2 m5.2 m15.5 m15.7 m14.3 m17.4 m12.8 m23.1 m25.4 m23.2 m13.2 m

Current Liabilities

54.9 m83.8 m53.7 m56.8 m80.7 m66.6 m57.1 m66.4 m70.6 m81.8 m95.8 m108.7 m115.4 m

Long-term debt

150 m150 m150 m150 m30 m

Total Debt

150 m150 m150 m150 m30 m

Total Liabilities

149.9 m125.3 m90.4 m81.9 m132.3 m122.2 m114.5 m127.9 m283.7 m297.9 m303 m311.3 m168.3 m

Additional Paid-in Capital

833.7 m1.8 b1.8 b1.8 b2.5 b2.5 b2.5 b2.5 b2.6 b2.6 b2.6 b3 b4 b

Retained Earnings

(563.9 m)(847.2 m)(891.3 m)(935.2 m)(1 b)(1.1 b)(1.2 b)(1.3 b)(1.4 b)(1.5 b)(1.8 b)(1.9 b)(2.2 b)

Total Equity

297.6 m955 m942.3 m904.5 m1.5 b1.4 b1.3 b1.2 b1.1 b1 b830.9 m1.1 b1.8 b

Financial Leverage

1.5 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.3 x1.4 x1.3 x1.1 x

Alnylam Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(89.2 m)(360.4 m)(290.1 m)(410.1 m)(490.9 m)

Depreciation and Amortization

10.2 m11.9 m19.1 m15.1 m13.4 m

Accounts Receivable

Inventories

Accounts Payable

1.8 m8.8 m1.7 m10.1 m(4.9 m)

Cash From Operating Activities

(68.7 m)(165.6 m)(189.1 m)(307.7 m)(382.8 m)

Purchases of PP&E

(4 m)(9 m)(13 m)(64.6 m)(104.2 m)

Cash From Investing Activities

(130.5 m)(548.8 m)(321.3 m)142.6 m(290.4 m)

Long-term Borrowings

(120 m)

Cash From Financing Activities

200.9 m736.5 m616.2 m177.8 m1.1 b

Interest Paid

1.1 m2.4 m

Income Taxes Paid

114 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(29.7 m)(250.9 m)(44.1 m)(44 m)(50.8 m)(71.8 m)(76.8 m)(103 m)(90.1 m)(104.1 m)(107.3 m)(141.2 m)

Depreciation and Amortization

3.2 m

Accounts Payable

6.2 m5.2 m15.5 m15.7 m14.3 m17.4 m12.8 m23.1 m25.4 m(9 m)

Cash From Operating Activities

(155.7 m)

Purchases of PP&E

(21.3 m)

Cash From Investing Activities

(134.8 m)

Cash From Financing Activities

41.5 m

Alnylam Pharmaceuticals Ratios

USDY, 2018

EV/EBIT

-68.6 x

EV/CFO

-64.9 x

Financial Leverage

1.1 x
Report incorrect company information